In vitro activity of immunosuppressive agents against Cryptococcus neoformans.
Amphotericin B
Anfotericina B
Ciclosporina A
Cryptococcus spp.
Cyclosporine A
Sinergia
Synergism
Tacrolimus
Journal
Enfermedades infecciosas y microbiologia clinica (English ed.)
ISSN: 2529-993X
Titre abrégé: Enferm Infecc Microbiol Clin (Engl Ed)
Pays: Spain
ID NLM: 101777541
Informations de publication
Date de publication:
04 Nov 2020
04 Nov 2020
Historique:
received:
10
07
2020
revised:
17
09
2020
accepted:
19
09
2020
entrez:
8
11
2020
pubmed:
9
11
2020
medline:
9
11
2020
Statut:
aheadofprint
Résumé
Infections caused by Cryptococcus neoformans are a major cause of fungal mortality in HIV-infected/AIDS patients and in those receiving organ transplants. We evaluated the in vitro activity of tacrolimus and cyclosporine in combination with amphotericin B and fluconazole against C. neoformans. MICs were determined against a total of 30 clinical isolates of C. neoformans by the microdilution method following the CLSI M27-A3 guidelines and by the checkerboard method. Tacrolimus and cyclosporine A showed in vitro activity against cryptococcal isolates. The combination of amphotericin B with cyclosporine A or tacrolimus was synergistic against 90% and 30% of isolates, respectively. Synergism was also observed with the combination of fluconazole with cyclosporine A or tacrolimus, against 70% and 20% of isolates, respectively. The synergistic interactions between the calcineurin inhibitors and antifungal drugs against C. neoformans isolates, could potentially have a role in devising novel therapeutic strategies for this opportunistic mycosis.
Identifiants
pubmed: 33160707
pii: S0213-005X(20)30308-6
doi: 10.1016/j.eimc.2020.09.014
pii:
doi:
Types de publication
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Publicado por Elsevier España, S.L.U. All rights reserved.